STEVENSON, Md., March 13, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of Henry Schein, Inc. (Nasdaq:HSIC) (“Henry Schein” or the “Company”) securities during the period between February 13, 2013 and February 12, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 7, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Henry Schein securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Henry Schein was engaging in anti-competitive behavior through agreements with Benco Dental Supply Company and Patterson Companies, Inc., in violation of United States antitrust laws, and these violations of U.S. antitrust laws would result in heightened scrutiny by the federal government and a lawsuit filed but the Federal Trade Commission (“FTC”).
According to the complaint, following a February 12, 2018 FTC announcement that it filed a complaint against Henry Schein, among others, alleging violations of U.S. antitrust laws, the value of Henry Schein shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Henry Schein securities purchased on or after February 13, 2013 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 



